Rempex Pharmaceuticals

Advancing novel therapeutics for the emerging threat of drug-resistant, Gram negative bacterial infections

Rempex was a leading developer of novel antibiotics, focusing on the emerging threat of drug-resistant Gram negative bacterial infections. The two most advanced assets in the company's pipeline are: Carbavance, a combination of a novel beta lactamase inhibitor with a carbapenem for treatment of hospitalized patients with severe infections; and RPX-602, an improved formulation of Minocin IV. Rempex was acquired by The Medicines Company in 2013, and The Medicines Company gained FDA approval for RPX-602 in 2015.


Acquired by The Medicines Company in 2013

Year of Investment



Life Sciences


Development-Stage Therapeutics


San Diego, California